BioSpace News Archive

AbbVie and Gedeon Richter Plc. announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases.

Prestige BioPharma Limited, a Singapore-based biopharmaceutical with operations in USA and South Korea, announced positive efficacy and safety results of the Phase 3 study for HD201, a biosimilar to Herceptin®, published in JAMA Oncology on March 4, 2022.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its acquisition of EPI Health, LLC (“EPI Health”), a specialty pharmaceutical company focused on the U.S. dermatology market.

Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or the “Company”), a leading gene and cell therapy group, is pleased to announce that it has completed its deal with Homology Medicines Inc.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data will be presented in eight posters at the World Sleep 2022 congress in Rome.

TFF Pharmaceuticals, Inc. today announced that President and CEO Glenn Mattes will be participating in a fireside chat at the 34th Annual Roth Conference in Dana Point, California March 13 - 15, 2022.

Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2022 on Friday, April 29, 2022.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administration (NMPA) has granted conditional approval to BeiGene’s anti-PD-1 antibody, tislelizumab.

Sierra Oncology, Inc. today announced the company will participate in the 32nd Annual Oppenheimer Healthcare Conference being held virtually from March 15-17, 2022.

The EP Group announced the acquisition of EPI Health, LLC by Novan, Inc..